In summary, although a Robo4 vaccination did not affect wound healing and organ integrity in tumor-bearing mice models, clinical evidence for the ability of Robo4-targeting strategies to avoid the known adverse effects of anti-VEGF therapy, namely, hypertension and proteinuria, is unavailable. This evidence concerns the gene ROBO4 and Hypertension.